Skip to main content
ACI
NYSE Trade & Services

Albertsons Q1 Misses, Slashes Outlook, and Launches Major Restructuring Amid Opioid Trial

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Negative
Importance info
8
Price
$11.295
Mkt Cap
$5.569B
52W Low
$10.86
52W High
$20.47
52W Position info
4.0% above low
Off High info
45% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

ACI is trading near its 52-week low of $10.86 (4.0% above the low).

Summary

Albertsons Q1 earnings missed expectations, prompting a full-year profit outlook cut and a major operational restructuring. The CFO is retiring, and opioid litigation risks are escalating with a Washington trial ongoing.


Key Events · Earnings and Guidance · ACI

  • Q1 Earnings Miss

    Net income fell to $84.7M ($0.17/share) from $236.4M a year ago. Adjusted EBITDA declined to $1,013M from $1,111M. Identical sales dropped 0.8%.

  • Full-Year Outlook Cut

    Management slashed its profit forecast, citing pressured unit volumes and value-conscious consumers. Identical sales are now expected to decline.

  • Major Restructuring (ACI Edge)

    Company is consolidating 11 divisions into 4 regions and centralizing center-store merchandising to improve efficiency and accountability.

  • CFO Retirement

    President and CFO Sharon McCollam will retire later this year; a successor search is underway.


Analysis · ACI · Trade & Services

A sharp drop in profitability underscores the quarter, with net income falling to $85M from $236M a year ago as margin compression and higher costs take hold. Identical sales declined 0.8% despite a 13% surge in digital growth. In response, the company announced a sweeping restructuring—ACI Edge—that consolidates divisions and centralizes merchandising, while also disclosing the retirement of its President and CFO. The opioid overhang remains critical: a Washington state trial is underway, and a Dallas County trial is set for September. On the balance sheet, $700M is drawn on the ABL and a $773.8M opioid settlement liability weighs, yet aggressive buybacks continue. The stock trades near its 52-week low, reflecting deep investor concern.

At the time of this filing, ACI was trading at $11.30 on NYSE in the Trade & Services sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $10.86 to $20.47. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACI - Latest Insights

ACI
Jul 23, 2026, 10:52 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $11.47
Real-time Price: $11.29 info
Change: -$0.175 (-2%) info
Market Cap: $5.569B info
ACI
Jul 23, 2026, 7:41 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $12.09
Real-time Price: $11.29 info
Change: -$0.8001 (-7%) info
Market Cap: $5.569B info
ACI
Jul 23, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.80
Real-time Price: $11.29 info
Change: -$1.51 (-12%) info
Market Cap: $5.569B info
ACI
Jul 23, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.80
Real-time Price: $11.29 info
Change: -$1.51 (-12%) info
Market Cap: $5.569B info
ACI
Jul 23, 2026, 7:29 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $12.08
Real-time Price: $11.29 info
Change: -$0.790 (-7%) info
Market Cap: $5.569B info